Tomorrow Investor

teloPR

telo-pr
Telo Genomics Initiates MRD Clinical Trial for Multiple Myeloma Patients
Toronto, Ontario–(Newsfile Corp. – February 13, 2024) – Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the “Company” or “Telo”) is pleased to announce that it has received the first patient sample for its clinical trial monitoring multiple...
telo-pr
Telo Genomics Engages US Diagnostics Experts to Power Product Adoption in the US
Toronto, Ontario–(Newsfile Corp. – January 30, 2024) – Telo Genomics Corp. (TSXV:...
Telo Genomics Presents Positive Results in Assessing MRD in Multiple Myeloma Patients at the International Myeloma Society Annual Meeting
Toronto, Ontario–(Newsfile Corp. – October 12, 2023) – Telo Genomics Corp. (TSXV:...
Telo Genomics Presents Positive Results in Assessing MRD in Multiple Myeloma Patients at the International Myeloma Society Annual Meeting
Toronto, Ontario–(Newsfile Corp. – October 12, 2023) – Telo Genomics Corp. (TSXV:...

Trending

No posts found

CATEGORIES

SIGNUP TO OUR NEWSLETTER

Subscribe

Get breaking market insights directly to your inbox

Add Calibre Mining to your Watchlist Today!